123 related articles for article (PubMed ID: 22077618)
1. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis.
Yoshimasu T; Ikeda T; Uede K; Kanazawa N; Furukawa F
J Dermatol; 2012 Jun; 39(6):536-40. PubMed ID: 22077618
[TBL] [Abstract][Full Text] [Related]
2. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
3. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H
Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
[TBL] [Abstract][Full Text] [Related]
4. Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.
Hidaka S; Kobayashi S; Iwagami M; Isshiki R; Tsutsumi D; Mochida Y; Ishioka K; Oka M; Maesato K; Moriya H; Ohtake T
Ren Fail; 2013; 35(1):43-8. PubMed ID: 23110683
[TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
Langevitz P; Buskila D; Lee P; Urowitz MB
J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
[TBL] [Abstract][Full Text] [Related]
6. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin.
Ferri C; Giuggioli D; Sebastiani M; Colaci M
Clin Exp Dermatol; 2007 May; 32(3):287-90. PubMed ID: 17397351
[TBL] [Abstract][Full Text] [Related]
8. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
9. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
[TBL] [Abstract][Full Text] [Related]
10. Digital ulcers score: a scoring system to assess digital ulcers in patients suffering from systemic sclerosis.
Ahrens HC; Siegert E; Tomsitz D; Mattat K; March C; Worm M; Riemekasten G
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):142-147. PubMed ID: 27749240
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
Gholam P; Sehr T; Enk A; Hartmann M
Dermatology; 2009; 219(2):171-3. PubMed ID: 19590168
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis.
Kato S; Kishiro I; Machida M; Fuse D; Yoshida T; Kaneko N
J Int Med Res; 2000; 28(6):258-68. PubMed ID: 11191719
[TBL] [Abstract][Full Text] [Related]
13. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Miyazaki M; Higashi Y; Goto C; Chayama K; Yoshizumi M; Sanada H; Orihashi K; Sueda T
J Cardiovasc Pharmacol; 2007 Apr; 49(4):221-7. PubMed ID: 17438407
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
15. Sarpogrelate: cardiovascular and renal clinical potential.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jul; 13(7):865-74. PubMed ID: 15212624
[TBL] [Abstract][Full Text] [Related]
16. Capillaroscopic findings in systemic sclerosis -- are they associated with disease duration and presence of digital ulcers?
Lambova S; Müller-Ladner U
Discov Med; 2011 Nov; 12(66):413-8. PubMed ID: 22127112
[TBL] [Abstract][Full Text] [Related]
17. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
[TBL] [Abstract][Full Text] [Related]
18. Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina.
Kajiwara I; Soejima H; Miyamoto S; Ogawa H
Thromb Res; 2011 Dec; 128(6):547-51. PubMed ID: 21722942
[TBL] [Abstract][Full Text] [Related]
19. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
20. Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.
Higashi Y; Miyazaki M; Goto C; Sanada H; Sueda T; Chayama K
J Cardiovasc Pharmacol; 2010 Jan; 55(1):56-61. PubMed ID: 19834330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
